Uncategorized
Complement inhibitor yields insignificant reduction in drusen volume
Eculizumab did not significantly reduce drusen volume in eyes with dry age-related macular degeneration, according to a study. Eculizumab, an inhibitor of terminal complement activation, is approved by the U.S. Food and Drug Administration for the treatment of paroxysmal nocturnal hemoglobinuria and atypical-hemolytic uremic syndrome.The COMPLETE study included 30 eyes of 30 patients; 20 eyes were randomized to receive intravenous Soliris (eculizumab, Alexion Pharmaceuticals) and 10 eyes received placebo. Patients received 600 mg to 1,200 mg doses of eculizumab for 24 weeks.